|
- Provisional CDC Guidelines for the Use and Safety Monitoring of . . .
Bedaquiline use in the treatment of pulmonary MDR TB should be accompanied by microbiologic monitoring with one sputum specimen submitted for culture monthly throughout and at end of treatment, even after conversion to negative culture, which is consistent with the standard approach to treatment and care of patients with MDR TB in the United
- Treatment for Drug-Resistant Tuberculosis Disease
People initiating treatment for MDR or rifampin-resistant TB but ineligible for BPaL (e g , resistance or intolerance to bedaquiline, pretomanid, or linezolid; severe extrapulmonary TB; pregnant; lactating; or aged less than 14 years) can receive an individualized regimen based on the 2019 guidelines Treatment of Drug-Resistant Tuberculosis
- Updated Guidelines on the Treatment of Drug-Susceptible and Drug . . .
The panel recommends a six-month treatment regimen (BPaL) of bedaquiline (B), pretomanid (P), and linezolid (L) for people aged 14 years or older with rifampin-resistant pulmonary TB disease and fluoroquinolone resistance or intolerance These regimens are also treatment options for people with an intolerance of rifampin
- Provisional CDC Guidelines for the Use and Safety Monitoring of . . .
To develop treatment guidelines for the use and safety monitoring of bedaquiline in the treatment of MDR TB, CDC’s Division of TB Elimination (DTBE) conducted a literature review of published clinical trials, reviewed results of other publicly available resources (transcript and background materials from the FDA Anti-Infectives Advisory
- Updates to Provisional Guidance for the Use of Pretomanid as Part of a . . .
Dear Colleague Letters May 4, 2023 Dear Colleagues, Today, CDC released updates to the 2022 "Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease " Updates include: A recommendation for an initial linezolid dose of 600 mg when using the BPaL regimen in the treatment of adults
- Molecular Detection of Drug Resistance (MDDR) in Mycobacterium . . .
CDC's Molecular Detection of Drug Resistance (MDDR) service can rapidly identify drug resistance, including multidrug-resistant, Mycobacterium tuberculosis complex This service utilizes DNA sequencing for detection of mutations most frequently associated with resistance to the most effective first and second-line drugs as well as new and repurposed drugs such as bedaquiline, clofazimine, and
- Clinical Overview of Drug-Resistant Tuberculosis Disease
Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB caused by TB bacteria that are resistant to: Isoniazid and rifampin, a fluoroquinolone, and a second-line injectable (amikacin, capreomycin, and kanamycin) or Isoniazid, rifampin, a fluoroquinolone, and bedaquiline or linezolid
- Reported Tuberculosis in the United States, 2023
The technical notes provide additional information about the data reported in the 2023 edition of Reported Tuberculosis in the United States
|
|
|